We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Incyte's Application for Pemigatinib Gets EMA's Validation
Read MoreHide Full Article
Incyte Corporation (INCY - Free Report) announced that the European Medicines Agency (EMA) has validated its Marketing Authorization Application (MAA) for its investigational FGFR inhibitor pemigatinib to treat adult patients with locally advanced/metastatic cholangiocarcinoma with a FGFR2 fusion or rearrangement that is relapsed or refractory after at least one line of systemic therapy. Cholangiocarcinoma is also known as bile-duct cancer.
The marketing application in Europe was based on data from the phase II FIGHT-202 study, which evaluated the safety and efficacy of pemigatinib in the given patient population.
We remind investors that in November 2019, the FDA accepted and granted a priority review to the new drug application (NDA) for pemigatinib as a second-line treatment of locally advanced or metastatic cholangiocarcinoma. A decision from the regulatory body is expected on May 30, 2020.
The NDA too was based on data from the phase II FIGHT-202 study. Results from the same showed that treatment with pemigatinib monotherapy led to an overall response rate (ORR) of 36% (primary endpoint) and a median duration of response (DOR) of 7.5 months (secondary endpoint) with a median follow-up of 15 months. No serious side effects were reported.
Shares of Incyte have increased 4.7% in the past year against its industry’s decrease of 2.4%.
Cholangiocarcinoma is often diagnosed at an advanced stage when the prognosis is poor. Hence a potential approval of pemigatinib both in the United States and Europe will provide a new treatment option for patients suffering this dreadful disease and drive growth for Incyte in the future.
Notably, in June 2019, Incyte initiated a phase III study on pemigatinib for the first-line treatment of patients with cholangiocarcinoma and FGFR2 fusions or rearrangements. The candidate is also being evaluated in a phase II study for bladder cancer.
We would like to remind investors that Agios Pharmaceuticals (AGIO - Free Report) is also evaluating its leukemia drug Tibsovo in the phase III ClarIDHy study for addressing previously treated patients with IDH1 mutant cholangiocarcinoma. The company plans to file a supplemental new drug application (sNDA) to the FDA for Tibsovo to treat cholangiocarcinoma. Currently, there are no treatment options available to treat this cancer.
Zacks Rank & Stocks to Consider
Incyte currently carries a Zacks Rank #4 (Sell). Better-ranked stocks in the biotech sector include Emergent Biosolutions Inc. (EBS - Free Report) and Alexion Pharmaceuticals, Inc. , both sporting a Zacks Rank #1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
Emergent’s earnings estimates have moved 5.6% north for 2020 over the past 60 days.
Alexion’s earnings estimates have been revised 0.4% upward for 2020 over the past 60 days.
The Hottest Tech Mega-Trend of All
Last year, it generated $24 billion in global revenues. By 2020, it's predicted to blast through the roof to $77.6 billion. Famed investor Mark Cuban says it will produce "the world's first trillionaires," but that should still leave plenty of money for regular investors who make the right trades early.
Image: Bigstock
Incyte's Application for Pemigatinib Gets EMA's Validation
Incyte Corporation (INCY - Free Report) announced that the European Medicines Agency (EMA) has validated its Marketing Authorization Application (MAA) for its investigational FGFR inhibitor pemigatinib to treat adult patients with locally advanced/metastatic cholangiocarcinoma with a FGFR2 fusion or rearrangement that is relapsed or refractory after at least one line of systemic therapy. Cholangiocarcinoma is also known as bile-duct cancer.
The marketing application in Europe was based on data from the phase II FIGHT-202 study, which evaluated the safety and efficacy of pemigatinib in the given patient population.
We remind investors that in November 2019, the FDA accepted and granted a priority review to the new drug application (NDA) for pemigatinib as a second-line treatment of locally advanced or metastatic cholangiocarcinoma. A decision from the regulatory body is expected on May 30, 2020.
The NDA too was based on data from the phase II FIGHT-202 study. Results from the same showed that treatment with pemigatinib monotherapy led to an overall response rate (ORR) of 36% (primary endpoint) and a median duration of response (DOR) of 7.5 months (secondary endpoint) with a median follow-up of 15 months. No serious side effects were reported.
Shares of Incyte have increased 4.7% in the past year against its industry’s decrease of 2.4%.
Cholangiocarcinoma is often diagnosed at an advanced stage when the prognosis is poor. Hence a potential approval of pemigatinib both in the United States and Europe will provide a new treatment option for patients suffering this dreadful disease and drive growth for Incyte in the future.
Notably, in June 2019, Incyte initiated a phase III study on pemigatinib for the first-line treatment of patients with cholangiocarcinoma and FGFR2 fusions or rearrangements. The candidate is also being evaluated in a phase II study for bladder cancer.
We would like to remind investors that Agios Pharmaceuticals (AGIO - Free Report) is also evaluating its leukemia drug Tibsovo in the phase III ClarIDHy study for addressing previously treated patients with IDH1 mutant cholangiocarcinoma. The company plans to file a supplemental new drug application (sNDA) to the FDA for Tibsovo to treat cholangiocarcinoma. Currently, there are no treatment options available to treat this cancer.
Zacks Rank & Stocks to Consider
Incyte currently carries a Zacks Rank #4 (Sell). Better-ranked stocks in the biotech sector include Emergent Biosolutions Inc. (EBS - Free Report) and Alexion Pharmaceuticals, Inc. , both sporting a Zacks Rank #1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
Emergent’s earnings estimates have moved 5.6% north for 2020 over the past 60 days.
Alexion’s earnings estimates have been revised 0.4% upward for 2020 over the past 60 days.
The Hottest Tech Mega-Trend of All
Last year, it generated $24 billion in global revenues. By 2020, it's predicted to blast through the roof to $77.6 billion. Famed investor Mark Cuban says it will produce "the world's first trillionaires," but that should still leave plenty of money for regular investors who make the right trades early.
See Zacks' 3 Best Stocks to Play This Trend >>